The Scientist

» industry and ecology

Most Recent

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: Study: Small Fish Comforted By Big Predators

Study: Small Fish Comforted By Big Predators

By | April 28, 2016

Baby fish show fewer signs of stress in the presence of large fish that scare off midsize predators. 

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

image: Pfizer-Allergan Merger Scrapped

Pfizer-Allergan Merger Scrapped

By | April 7, 2016

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.

0 Comments

image: Book Excerpt from <em>The Serengeti Rules</em>

Book Excerpt from The Serengeti Rules

By | April 1, 2016

In the introduction to the book, author Sean B. Carroll draws the parallels between ecological and physiological maladies.

0 Comments

image: Contributors

Contributors

By | April 1, 2016

Meet some of the people featured in the April 2016 issue of The Scientist.

0 Comments

image: Parallel Plagues

Parallel Plagues

By | April 1, 2016

Like cancer, ecological scourges result from the breakdown of regulatory processes, and may be treated with similar logic.

0 Comments

image: Another Drug Price Hike

Another Drug Price Hike

By | March 28, 2016

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

0 Comments

image: Science Exchange Raises $25M

Science Exchange Raises $25M

By | March 24, 2016

With fresh funding, the experiment-services and independent-validation startup will expand its staff.

0 Comments

Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS